Harrow, Inc.

HROW ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013
Revenue $26.8M $19.9M $9.7M $1.7M $10.0K
Cost of Revenue $13.5M
Gross Profit $13.3M $10.1M $4.5M $567.0K $10.0K
Gross Margin 49.6% 50.7% 46.4% 34.2% 100.0%
Operating Expenses
Research & Development $413.0K $739.0K $332.0K $237.0K $1.6M
SG&A Expense $25.0M $17.6M $12.5M $8.1M $6.1M
Operating Income $-12.2M $-15.9M $-14.8M $-10.1M $-7.7M
Operating Margin -45.4% -79.6% -152.6% -611.3% -76,868.8%
Interest Expense $3.8K
Pretax Income $-12.9M $-19.2M
Income Tax Expense $-935.0K $-111.0K $5.0K $3.0K
Net Income $-12.0M $-19.1M $-15.9M $-10.1M $-7.6M
Net Margin -44.8% -95.7% -163.6% -609.5% -76,431.2%
EPS (Basic) $-0.60 $-1.50 $-1.66 $-1.11 $-0.88
EPS (Diluted) $-0.60 $-1.50 $-1.66 $-1.11 $-0.88
Shares Outstanding (Basic) 20.0M 18.6M 9.8M 9.3M 9.0M
Shares Outstanding (Diluted) 20.0M 18.6M 9.8M 9.3M 9.0M
Dividends Per Share
← Newer Page 2 of 2 Older →